Top Page
Alterity Therapeutics
(Sydney:ATH)
Alterity Therapeutics (ATH) vs. iShares MSCI Australia ETF (EWA)
Alterity Therapeutics Business Overview & Revenue Model
Alterity Therapeutics Financial Statement Overview
| Breakdown | |||||
| TTM | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 3.72M | 4.02M | 3.92M | 5.12M | 4.34M | 0.00 | Gross Profit |
| 3.59M | 3.80M | 3.63M | 4.76M | 3.98M | -112.43K | EBIT |
| -22.59M | -19.60M | -14.64M | -15.50M | -15.18M | -10.41M | EBITDA |
| -22.14M | -19.57M | -17.51M | -17.39M | -19.36M | -13.34M | Net Income Common Stockholders |
| -19.79M | -19.12M | -13.81M | -12.85M | -15.31M | -9.70M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 4.54M | 12.64M | 15.77M | 34.81M | 28.12M | 9.20M | Total Assets |
| 10.55M | 19.22M | 27.32M | 41.36M | 33.59M | 13.30M | Total Debt |
| 105.83K | 159.04K | 210.38K | 117.49K | 65.65K | 33.75K | Net Debt |
| -4.43M | -12.48M | -15.56M | -34.69M | -28.05M | -9.16M | Total Liabilities |
| 2.76M | 5.43M | 4.50M | 5.89M | 3.12M | 2.76M | Stockholders Equity |
| 7.79M | 13.80M | 22.81M | 35.47M | 30.47M | 10.55M |
| Cash Flow | Free Cash Flow | ||||
| -16.47M | -12.61M | -20.04M | -12.43M | -17.34M | -9.45M | Operating Cash Flow |
| -16.47M | -12.61M | -20.04M | -12.34M | -17.33M | -9.43M | Investing Cash Flow |
| -722.00 | -5.72K | -36.46K | -89.15K | -10.47K | -16.74K | Financing Cash Flow |
| 8.46M | 9.22M | 124.34K | 16.30M | 36.69M | 3.98M |
Alterity Therapeutics Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
79 Outperform | AU$85.86M | 8.85 | 45.86% | 2.20% | 71.65% | 152.89% | |
54 Neutral | $5.38B | 3.31 | -45.11% | 3.29% | 16.82% | 0.04% | |
51 Neutral | $109.53M | ― | -154.88% | ― | ― | 20.00% | |
46 Neutral | AU$92.28M | ― | ― | ― | -33.01% | ||
41 Neutral | $119.47M | ― | -99.05% | ― | ― | -34.09% | |
40 Underperform | AU$116.83M | ― | -46.65% | ― | 96.20% | 80.90% | |
40 Underperform | AU$89.97M | ― | -85.35% | ― | 315.11% | 51.16% |
Alterity Therapeutics Corporate Events
The Bank of New York Mellon Corporation (BNYMC) has increased its substantial holding in Alterity Therapeutics Limited, now holding a 27.03% voting power compared to the previous 26.01%. This change indicates a growing interest and confidence in Alterity’s operations, potentially impacting the company’s market positioning and stakeholder relations.
Alterity Therapeutics announced significant findings from its clinical programs at the 2025 International MSA Congress, highlighting the efficacy of its ATH434 treatment in reducing disease severity and improving symptoms in MSA patients. The introduction of the MSA Atrophy Index as a diagnostic and monitoring tool, along with insights from the bioMUSE study, underscores Alterity’s commitment to advancing MSA treatment and enhancing diagnostic capabilities, potentially impacting patient care and clinical practices.
The Bank of New York Mellon Corporation (BNYMC) has increased its voting power in Alterity Therapeutics Limited from 24.95% to 26.01%, as of May 8, 2025. This change in substantial holding indicates a strengthened position for BNYMC in the company, potentially impacting Alterity’s strategic decisions and shareholder dynamics.
Alterity Therapeutics announced its participation in the 2025 International MSA Congress, where it will present multiple oral and poster presentations on its clinical programs for Multiple System Atrophy (MSA). The presentations will highlight the Phase 2 data for ATH434, which has shown significant clinical efficacy and safety in treating MSA. The company’s involvement in the congress underscores its commitment to advancing MSA research and care, further supported by the recent Fast Track Designation for ATH434 by the US FDA.
Alterity Therapeutics announced that the U.S. FDA has granted Fast Track designation for its lead candidate, ATH434, aimed at treating Multiple System Atrophy (MSA). This designation is expected to accelerate the development and review process of ATH434, highlighting its potential to meet the high unmet need for MSA treatments. The Fast Track status allows Alterity to engage more frequently with the FDA, potentially speeding up the path to approval. The company has demonstrated ATH434’s efficacy and safety in Phase 2 trials, showing significant improvements in clinical outcomes for MSA patients.
Alterity Therapeutics announced promising results from their ATH434-201 Phase 2 clinical trial at the European MSA Symposium. The trial demonstrated that ATH434 significantly reduced disease severity in MSA patients, with improvements in daily living activities and motor performance. ATH434 was well tolerated, showing potential for further development in treating MSA, a rare neurodegenerative disorder. The study’s positive outcomes, including target engagement and brain volume preservation, support the continued advancement of ATH434, which has been granted Orphan Drug Designation by the U.S. FDA and the European Commission.
Alterity Therapeutics Limited has released a report detailing the top 20 holders of its listed options, which are set to expire on February 26, 2027, with a price of $0.028. The report highlights that UBS Nominees Pty Ltd holds the largest percentage of these options at 29.25%, followed by Citicorp Nominees Pty Limited with 18.11%. This information provides insights into the distribution of holdings among major investors, which could have implications for the company’s market strategy and investor relations.
Alterity Therapeutics Limited announced the quotation of a new class of options on the Australian Securities Exchange, with an exercise price of $0.028 and an expiration date in February 2027. This move signifies a strategic financial decision aimed at enhancing the company’s capital structure, potentially impacting its market positioning and providing stakeholders with new investment opportunities.
Alterity Therapeutics Ltd. has released a presentation that may contain forward-looking statements in accordance with US Securities Laws. These statements involve risks and uncertainties that could cause actual results to differ materially from expectations, highlighting the importance of consulting their 2024 Form 20-F for detailed risk factors.
Alterity Therapeutics Ltd. has announced a prospectus offering new options to selected participants, including a placement offer and a broker offer. The options, which have an exercise price of A$0.028 and expire in February 2027, aim to raise capital and potentially strengthen the company’s financial position, impacting its future operations and market strategy.
Alterity Therapeutics Ltd. has announced topline data from a Phase 2 study of ATH434, a treatment for Multiple System Atrophy (MSA), presented at the American Academy of Neurology Annual Meeting in 2025. The study was a randomized, double-blind, placebo-controlled trial, indicating a significant step in the company’s research efforts, potentially impacting its position in the neurology field and offering new hope for stakeholders involved in MSA treatment development.
Alterity Therapeutics Ltd. announced a change in the director’s interest, with Peter Marks acquiring 1,818,182 fully paid ordinary shares through a placement at $0.011 per share. This acquisition reflects an increase in Marks’ stake in the company, potentially signaling confidence in Alterity’s strategic direction and future prospects, which could influence investor sentiment and market perception.
Alterity Therapeutics Ltd has announced that Regal Funds Management Pty Ltd and its associates have become substantial holders in the company as of April 4, 2025. Regal Funds Management now holds a significant voting power with 1,255,948,179 ordinary shares, representing a substantial interest in Alterity Therapeutics. This development indicates a strategic move by Regal Funds Management, potentially impacting Alterity’s market positioning and stakeholder dynamics.
The Bank of New York Mellon Corporation (BNYMC) has reported a change in its substantial holding in Alterity Therapeutics Ltd., with its voting power decreasing from 33.96% to 24.95%. This shift in voting power could impact BNYMC’s influence over company decisions, potentially affecting Alterity’s strategic direction and stakeholder interests.
Alterity Therapeutics has successfully completed a two-tranche placement, raising A$38.79 million, with significant participation from its leadership and board. The funds will be used to accelerate the regulatory and development activities for its lead candidate ATH434, which has shown positive results in Phase 2 trials for MSA and has received Orphan Drug Designation in the U.S. and Europe. This financial boost is expected to enhance Alterity’s position in the biotechnology industry, allowing it to further its research and development efforts in neurodegenerative diseases.
Alterity Therapeutics Ltd. announced the issuance of 2,470,521,806 fully paid ordinary shares without disclosure under Part 6D.2 of the Corporations Act, as permitted by section 708A(5)(e). The company has confirmed compliance with relevant provisions of the Corporations Act and stated that there is no excluded information to disclose, ensuring transparency and adherence to regulatory requirements.
Alterity Therapeutics Limited has announced the quotation of over 2.47 billion fully paid ordinary securities on the Australian Securities Exchange. This move is part of previously announced transactions and is expected to enhance the company’s financial flexibility, potentially impacting its market positioning and providing opportunities for growth and development in its therapeutic areas.
Alterity Therapeutics announced positive results from their ATH434 Phase 2 clinical trial, which will be presented at the American Academy of Neurology Annual Meeting. The trial showed significant improvements in patients with early-stage Multiple System Atrophy (MSA), with ATH434 demonstrating efficacy in reducing disability and improving motor performance. The use of wearable sensors in the study indicated increased activity levels in patients, and the drug showed potential in reducing iron accumulation in the brain, suggesting a promising impact on the treatment of MSA.
Alterity Therapeutics Ltd. held an Extraordinary General Meeting where several resolutions regarding the issuance of shares, options, and securities were passed with significant support. The approval of these resolutions is expected to enhance the company’s financial flexibility and strategic positioning, potentially benefiting stakeholders by facilitating future growth and development initiatives.
Alterity Therapeutics Limited has announced the application for the quotation of new securities on the Australian Securities Exchange (ASX). This move involves the issuance of 161 fully paid ordinary shares, reflecting the company’s ongoing efforts to enhance its financial standing and operational capabilities. The announcement is part of Alterity’s strategic initiatives to strengthen its market position and support its research and development activities, potentially impacting its stakeholders by providing additional resources for advancing its therapeutic projects.
JPMorgan Chase & Co. and its affiliates have become substantial holders in Alterity Therapeutics Ltd, acquiring a 5.13% voting power in the company. This acquisition signifies a notable investment by a major financial institution, potentially impacting Alterity Therapeutics’ market position and stakeholder interests.